Relationship between structure and P-glycoprotein inhibitory activity of dimeric peptides related to the Dmt-Tic pharmacophore

被引：3

作者：

Ambo, Akihiro ^{[1
]}

Ohkatsu, Hiromichi ^{[1
]}

Minamizawa, Motoko ^{[1
]}

Watanabe, Hideko ^{[1
]}

Sugawara, Shigeki ^{[1
]}

Nitta, Kazuo ^{[1
]}

Tsuda, Yuko ^{[2
]}

Okada, Yoshio ^{[2
]}

Sasaki, Yusuke ^{[1
]}

机构：

[1] Tohoku Pharmaceut Univ, Aoba Ku, Sendai, Miyagi 9818558, Japan

[2] Kobe Gakuin Univ, Chuo Ku, Kobe, Hyogo 6508586, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 06期

关键词：

Dimeric peptide analogs; P-glycoprotein inhibitory activity; Structure-activity relationship; Dmt-Tic pharmacophore; BLOOD-BRAIN-BARRIER; MULTIDRUG-RESISTANCE; D-PENICILLAMINE(2,5) ENKEPHALIN; ANALOGS; ANTINOCICEPTION; TRANSPORTER; BINDING; CANCER; POTENT; DRUGS;

D O I：

10.1016/j.bmcl.2012.01.107

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

To develop novel inhibitors of P-glycoprotein (P-gp), dimeric peptides related to an opioid peptide containing the Dmt-Tic pharmacophore were synthesized and their P-gp inhibitory activities were analyzed. Of the 30 analogs synthesized, N-alpha,N-epsilon-[(CH3)(2)Mle-Tic](2)Lys-NH2 and its D-Lys analog were found to exhibit potent P-gp inhibitory activity, twice that of verapamil, in doxorubicin-resistant K562 cells. Structure-activity studies indicated that the correct hydrophobicity and spacer length between two aromatic rings are important structural elements in this series of analogs for inhibition of P-gp. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：2192 / 2194

页数：3

共 19 条

[1] Opioid receptor-like 1 (ORL1) receptor binding and the biological properties of Ac-Arg-Tyr-Tyr-Arg-lie-Arg-NH2 and its analogs
Ambo, A.
Kohara, H.
Kawano, S.
Sasaki, Y.
[J]. JOURNAL OF PEPTIDE SCIENCE, 2007, 13 (10) : 672 - 678
[2] DETECTION OF P-GLYCOPROTEIN IN OVARIAN-CANCER - A MOLECULAR MARKER ASSOCIATED WITH MULTIDRUG RESISTANCE
BELL, DR
GERLACH, JH
KARTNER, N
BUICK, RN
LING, V
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) : 311 - 315
[3] Enhanced antinociception of the model opioid peptide [D-Penicillamine2,5] enkephalin by P-glycoprotein modulation
Chen, CP
Pollack, GM
[J]. PHARMACEUTICAL RESEARCH, 1999, 16 (02) : 296 - 301
[4] Chen CP, 1998, J PHARMACOL EXP THER, V287, P545
[5] BLOOD-BRAIN-BARRIER RESTRICTION OF PEPTIDES AND LOW UPTAKE OF ENKEPHALINS
CORNFORD, EM
BRAUN, LD
CRANE, PD
OLDENDORF, WH
[J]. ENDOCRINOLOGY, 1978, 103 (04) : 1297 - 1303
[6] EXPRESSION OF A MULTIDRUG-RESISTANCE GENE IN HUMAN-TUMORS AND TISSUES
FOJO, AT
UEDA, K
SLAMON, DJ
POPLACK, DG
GOTTESMAN, MM
PASTAN, I
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (01) : 265 - 269
[7] GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163
[8] HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435
[9] From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
Litman, T
Druley, TE
Stein, WD
Bates, SE
[J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (07) : 931 - 959
[10] Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity
Litman, T
Zeuthen, T
Skovsgaard, T
Stein, WD
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1997, 1361 (02): : 159 - 168

← 1 2 →